Unknown

Dataset Information

0

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.


ABSTRACT:

Background

CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.

Methods

This phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. Control salvage treatment was usually based on cytarabine and anthracycline, often with 1 or more additional agents. Survival at 1 year was the primary efficacy end point.

Results

Patient characteristics were well balanced between the 2 study arms. Improvements in efficacy outcomes were observed following CPX-351, but did not meet prospectively defined statistical criteria for 1-year survival improvement in the overall population. Subset analyses of the EPI-defined poor-risk strata demonstrated higher response rates (39.3% vs 27.6%) and improvements in event-free survival (HR, 0.63; P = .08) and overall survival (HR, 0.55; P = .02). Also, 60-day mortality was lower in the CPX-351 study arm for poor-risk patients (16.1% vs 24.1%).

Conclusions

Taken together, the data suggest possible improved outcomes in CPX-351-treated first relapse AML patients with EPI-defined poor-risk disease.

SUBMITTER: Cortes JE 

PROVIDER: S-EPMC5542857 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Cortes Jorge E JE   Goldberg Stuart L SL   Feldman Eric J EJ   Rizzeri David A DA   Hogge Donna E DE   Larson Melissa M   Pigneux Arnaud A   Recher Christian C   Schiller Gary G   Warzocha Krzysztof K   Kantarjian Hagop H   Louie Arthur C AC   Kolitz Jonathan E JE  

Cancer 20140915 2


<h4>Background</h4>CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.<h4>Methods</h4>This phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (E  ...[more]

Similar Datasets

| S-EPMC6127025 | biostudies-literature
| S-EPMC4237711 | biostudies-literature
| S-EPMC4624448 | biostudies-literature
| S-EPMC6003284 | biostudies-literature
| S-EPMC5756117 | biostudies-literature
| S-EPMC10686991 | biostudies-literature
| S-EPMC6306103 | biostudies-literature
| S-EPMC4382783 | biostudies-literature
| S-EPMC4520927 | biostudies-literature
| S-EPMC9221356 | biostudies-literature